CSPC Pharmaceutical Group

Company snapshot

CSPC was established in 1997. Since the very beginning, CSPC has taken “All for better medicine, all for a healthier world.” as the corporate mission. During all links of development, purchase, production and circulation, we devote ourselves to guaranteeing the health of people by focusing on creating high-quality, effective, reliable, and innovative medicines that meet the needs of community. Inn

• 1 active pipeline program(s) linked via ClinicalTrials.gov.
• 1 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for CSPC Pharmaceutical Group. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for CSPC Pharmaceutical Group.

1. Jun 8, 2026 Clinical update

   paclitaxel cationic liposome for injection — Phase 1

View all clinical trial activity →

• What is CSPC Pharmaceutical Group?

  CSPC Baike (Shandong) is a biotech organization headquartered in CN. Primary therapeutic focus areas include Colorectal Liver Metastases. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov,

• Is CSPC Pharmaceutical Group publicly traded?

  CSPC Pharmaceutical Group appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does CSPC Pharmaceutical Group develop or market?

  We link 2 drug profile(s) where CSPC Pharmaceutical Group is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/cspc-baike-shandong-biopharmaceutical-co#company-drugs.

• What are the latest developments for CSPC Pharmaceutical Group?

  In the last 12 months our linked public records show 1 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does CSPC Pharmaceutical Group focus on?

  CSPC Pharmaceutical Group focuses on Colorectal Liver Metastases based on our analysis of their pipeline programs and drug development activities.